We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Acamprosate for Treatment of Compulsive Behaviors and Craving in Parkinson's Disease

This study has been withdrawn prior to enrollment.
(PI left site)
Sponsor:
ClinicalTrials.gov Identifier:
NCT00640952
First Posted: March 21, 2008
Last Update Posted: November 13, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
National Parkinson Foundation
Information provided by (Responsible Party):
Joohi Jimenez-Shahed, Baylor College of Medicine
  Purpose
The purpose of this study is to determine how many patients with Parkinson's disease have compulsive behaviors, and what types of behaviors they have. This study will also determine if acamprosate can be used to treat compulsive behaviors in Parkinson's disease patients.

Condition Intervention
Parkinson's Disease Drug: acamprosate

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Acamprosate for Treatment of Compulsive Behaviors and Craving in Parkinson's Disease

Resource links provided by NLM:


Further study details as provided by Joohi Jimenez-Shahed, Baylor College of Medicine:

Primary Outcome Measures:
  • safety and efficacy compared to baseline scores [ Time Frame: 6 months ]

Secondary Outcome Measures:
  • change from baseline assessment tools used in the study [ Time Frame: 6 months ]

Enrollment: 0
Study Start Date: August 2006
Study Completion Date: September 2008
Primary Completion Date: September 2008 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: acamprosate
    333 mg 2 tabs tid
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Idiopathic Parkinson's disease
  2. Active dopaminergic therapy at stable dose for one month (levodopa or dopamine agonist)
  3. Able and willing to complete Rating Scales
  4. Presence of one or more compulsive behavior based on responses to Rating Scales (defined as >5 on the SOGS; >17 on the YBOCS-SV and YBOCS-CUV; >1.7 on the SCS for women and >2.1 on the SCS for men; >15 on the YBOCS-BE, >5.5 on the CQ).
  5. Written informed consent

Inclusion criteria (controls):

  1. No significant psychiatric disease
  2. Able and willing to complete Rating Scales
  3. Written informed consent

Exclusion Criteria:

  1. No anticipated need for adjustment of medications for Parkinson's disease
  2. Current participation in another clinical study
  3. History of unstable psychiatric disease (as determined by the Principal Investigator)
  4. Women of childbearing age not using appropriate contraceptive methods (oral contraceptives, condoms, surgery)
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00640952


Locations
United States, Texas
PDCMDC 6550 Fannin, Suite 1801
Houston, Texas, United States, 77030
Sponsors and Collaborators
Baylor College of Medicine
National Parkinson Foundation
Investigators
Principal Investigator: Joohi Jimenez-Shahed, MD Baylor College of Medicine
  More Information

Additional Information:
Responsible Party: Joohi Jimenez-Shahed, Principal Investigator, Baylor College of Medicine
ClinicalTrials.gov Identifier: NCT00640952     History of Changes
Other Study ID Numbers: H-19781
First Submitted: December 28, 2007
First Posted: March 21, 2008
Last Update Posted: November 13, 2015
Last Verified: November 2015

Keywords provided by Joohi Jimenez-Shahed, Baylor College of Medicine:
Parkinson's disease
impulse control behaviors
dopa-dysregulation

Additional relevant MeSH terms:
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases
Compulsive Behavior
Impulsive Behavior
Acamprosate
Alcohol Deterrents